Nasdaq atai.

In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. ... NASDAQ: ATAI Atai Life Sciences. Market Cap. $173M. Today's Change (-7.14% ...Nov 30, 2023 · Atai Life Sciences (NASDAQ:ATAI) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior business?We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings. Company profile for ATAI Life Sciences N.V. including key executives, insider trading, ownership, revenue and average growth rates. View detailed ATAI description & address.BEIJING, Aug. 06, 2019 (GLOBE NEWSWIRE) -- ATA Inc. ("ATA" or the "Company", Nasdaq: ATAI), a company focused on providing students with quality educational experiences and services in China and ...Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...

- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine ...

Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 ...Atai Life Sciences (NASDAQ: ATAI) focuses on therapeutics to treat mental health issues, such as anxiety, depression or addiction. This clinical-stage biopharma company went public in June 2021.

Get ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ...View live ATAI Life Sciences N.V. chart to track its stock's price action. Find market predictions, ATAI financials and market news.Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix.. PsyProtix is a precision psychiatry company focused ...Dec 23, 2022 · NEW YORK and BERLIN, Dec. 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical stage biopharmaceutical company aiming to transform the ... Atai Life Sciences (NASDAQ: ATAI) focuses on therapeutics to treat mental health issues, such as anxiety, depression or addiction. This clinical-stage biopharma company went public in June 2021.

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release.

Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 million to advance multiple clinical and discovery programs.

NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the …NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Atai Life Sciences (NASDAQ:ATAI) is one of the leading biotech companies discovering and developing treatments derived from psychedelic compounds. Atai already has an MDMA-derived drug in its ...NL0015000DX5. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more.

Mar 7, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, ATAI Life Sciences has an average price target of $15.33 with a high of $23.00 and a low of $9.00. Below is a summary ... Nov 14, 2023 · Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Cash, cash ... Atai Life Sciences (Nasdaq: ATAI) Always at the top of the list of psychedelics companies on the move, Atai Life Sciences launched a Phase 1 study of an MDMA derivative focusing on post-traumatic stress disorder in September.More from Bloomberg. Stock analysis for ATAI Life Sciences NV (ATAI:NASDAQ GM) including stock price, stock chart, company news, key statistics, …Atai Life Sciences (NASDAQ: ATAI) is another clinical-stage biopharmaceutical company that seeks to transform the treatment of mental health conditions using innovative psychedelic-based drugs ...The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions.Other companies interested in the use of traditional, naturally derived ibogaine for substance abuse include DemeRx, a subsidiary of Peter Thiel-backed Atai Life Sciences (NASDAQ:ATAI), and ...

ATAI Stock Price | ATAI Life Sciences N.V. Stock Quote (U.S.: Nasdaq ...

NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.1Y 5Y No 1Y chart data available About ATAI ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and …Through its subsidiary Perception Neuroscience, atai Life Sciences N.V. (NASDAQ:ATAI) recently released an update on another platform for treatment resistant depression (TRD) that's derived from a ...DarioGaona/iStock via Getty Images. Atai Life Sciences (NASDAQ:ATAI) has been making great progress in advancing several drugs from its pipeline on multiple fronts.In particular, it is advancing a ...ATAI Life Sciences N.V. Common Shares (ATAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. To date, the VC focus on psychedelics hasn’t proven much of a return on investment. FDA approval of drugs like psilocybin and MDMA is likely years away. The stock price of psychedelic therapy companies has tanked in recent years. In March 2023, Atai Life Sciences noted that it had laid off roughly 30% of its employees.Lucy Scientific Discovery(NASDAQ:LSDI) Holding Weight: 4.84%; Atai Life Sciences(NASDAQ:ATAI) Holding Weight: 4.71%; PSIL Sector Exposure. PSIL Industry Exposure. Full Holdings Details. Similar ETFs. iShares Future Cloud 5G and Tech ETF NYSEARCA:IDAT; Global X Solar ETF NASDAQ:RAYS;Download Historical Stock Quotes for Atai Life Sciences N.V. [NASDAQ,ATAI] in a range of formats.atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates. “As the burden of unmet medical needs in mental health care continues to grow, our team remains …COMPASS Pathways (NASDAQ:CMPS), GH Research (NASDAQ:GHRS), atai Life Sciences (NASDAQ:ATAI), IntelGenx Technologies (OTCQB:IGXT) and Filament Health (OTCQB:FLHLF) reported their first quarter ...

We have applied to list our common shares on the Nasdaq Global Market under the symbol “ATAI.” We are an “emerging growth company” as defined under the U.S. ...

DemeRx, a subsidiary of Atai Life Sciences (NASDAQ: ATAI), is developing psychedelic ibogaine for the treatment of opioid use disorder and just announced it has begun a phase 1/2a clinical trial on healthy volunteers and recreational drug users. Ibogaine is a dissociative psychoactive compound naturally found in the iboga tree, which is a …

Company Description. ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive …To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.Dear fellow shareholders of atai Life Sciences, Biotech has been a tough sector for investors over the last 24 months. More or less since the IPO in June 2021 of atai Life Sciences (Nasdaq: ATAI ...NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...How much insider buying is happening at Atai Life Sciences? Insiders have purchased a total of 1,618,685 ATAI shares in the last 24 months for a total of $3,116,715.96 bought.According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...The fund has raised an initial $35 million in capital and currently holds an active portfolio of 20 companies, including investments in Atai Life Sciences (NASDAQ: ATAI), Reset Pharma, Field Trip ...NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated coverage of ATAI Life Sciences N.V. (NASDAQ:ATAI) with a Buy recommendation. Analyst Price Forecast Suggests 605.71% Upside. As ...Cramer said he likes Enterprise Products Partners L.P. (NYSE:EPD) as it has good dividend, growing volumes and solid management. The "Mad Money" host said Doximity, Inc. (NASDAQ:DOCS) is good, but ...I’ve also been asked if it’s proper and ethical that COMPASS Pathways (Nasdaq: CMPS) and atai Life Sciences (Nasdaq: ATAI) own the majority of the patents around those psychedelics.Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in the first quarter of 2023.

Atai Life Sciences N.V. (NASDAQ:ATAI) is a promising clinical-stage biopharmaceutical company that creates and funds businesses focusing on developing psychedelic-based treatments.The fund has raised an initial $35 million in capital and currently holds an active portfolio of 20 companies, including investments in Atai Life Sciences (NASDAQ: ATAI), Reset Pharma, Field Trip ...ATAI Life Sciences (NASDAQ:ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ...Nov 29, 2023 · According to 4 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,110.76% from the latest price. Instagram:https://instagram. dall e 3 freebest bank to open an account in michigannintendo of japantop rated forex broker atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the launch of TryptageniX. msft aibest crypto to day trade Jul 14, 2021 · Some of the companies already making a big splash in the as yet small sector include COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), and Seelos Therapeutics, Inc ... Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. CI. Nov. 14. Atai Life Sciences N.V. acquired … etf vtv Jan 18, 2022 ... In December, it was announced that atai would be added to the Nasdaq's prestigious biotechnology index. ... Atai Life Sciences Has Been Selected ...Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...